Regulators, developers, and testing laboratories are exploring in silico models, transporter assays, and other options to better predict drug combination outcomes In the future, many drug–drug ...
A research team led by Associate Professor Noriyuki Kurita from the Department of Computer Science and Engineering at Toyohashi University of Technology and by Associate Professor Pornpan Pungpo from ...
The evaluation of Cytochrome P450 (CYP) enzymatic activity is essential to estimate drug pharmacokinetics. Numerous CYP allelic variants have been identified; the functional characterisation of these ...
Scientists explored selectively blocking the CYP3A4 protein responsible for breaking down large swaths of approved drugs, providing a way to improve drug efficacy. Scientists at St. Jude Children's ...
Alexis Garcia, PharmD, senior director of business development at Tabula Rasa HealthCare, outlines how cytochrome P450 enzymes can impact medication efficacy in patients taking multiple drugs. So the ...
Suraxavir marboxil (GP681) is an orally available prodrug that is converted in vivo to the active metabolite GP1707D07, a PA-targeting antiviral against influenza. Because GP1707D07 is primarily ...
Cytochrome P450 (CYP) 3A4 is the most studied, and yet probably the most challenging, drug-metabolizing enzyme for those involved in drug R&D. Now, a report in PNAS sheds further light on the ...
Cytochromes P450 are a superfamily of enzymes containing heme as a cofactor that function as monooxygenases. Suppressed drug metabolism was identified in patients with various inflammatory conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results